secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scienture Holdings, Inc. (SCNX)
CIK:        0001382574
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001493152-24-021967
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TRxADE Health receives Nasdaq non-compliance notice for late Q1 10-Q; directors resign, new ones appointed
--------------------------------------------------------------------------------

- Received Nasdaq notice on May 23, 2024 for failing to timely file Q1 10-Q; must submit compliance plan by July 22, 2024.
- Potential extension to Nov 18, 2024; no immediate effect on listing or trading.
- Appointed Mayur Doshi (CEO of AlfaGene Bioscience) and Narasimhan Mani (former CEO of Kesin Pharma) as directors on May 28, 2024.
- Directors Jeff Newell and Michael Peterson voluntarily resigned on May 30, 2024; no dispute with the Company.
- Resigned directors receive cash compensation through June 30, 2024; unvested shares fully vested on resignation date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382574/000149315224021967/0001493152-24-021967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382574/000149315224021967/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-021967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer